C2 PHARMA EXPANDS OPHTHALMIC API PORTFOLIO WITH THE LAUNCH OF DORZOLAMIDE HYDROCHLORIDE

Cork, Ireland, March 11th, 2026 – C2 PHARMA, the global leader in ophthalmic active pharmaceutical ingredients (APIs), announces the addition of Dorzolamide Hydrochloride to its expanding ophthalmology portfolio.

The process validation campaign for Dorzolamide Hydrochloride was successfully finalized in early March 2026, with the filing of the Certificate of Suitability (CEP) and the submission of the US Drug Master File (US-DMF) planned for April 2026 to support global regulatory requirements.

Dorzolamide Hydrochloride is a carbonic anhydrase inhibitor commonly prescribed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension. As a well-established therapy in ophthalmology, it plays an important role in long-term intraocular pressure management and is frequently used both as monotherapy and in combination with other treatments.

C2 PHARMA has partnered with its long-standing contract manufacturing partner, Haleos Labs limited (formerly SMS Lifesciences), for the production of Dorzolamide Hydrochloride, ensuring reliable manufacturing capacity and supply continuity. The addition of Dorzolamide Hydrochloride further strengthens C2 PHARMA’s growing portfolio of ophthalmic APIs and underlines the company’s commitment to providing reliable, high-quality, and cost-competitive solutions to the global pharmaceutical industry. The planned launch of Brinzolamide in Q2 2026 will further expand C2 PHARMA’s ophthalmology portfolio.

Meet the C2 PHARMA team at DCAT Week in New York, March 23–26, 2026 (The Benjamin Hotel, Suite 2202) or contact info@c2pharma.com to schedule a meeting.